Gilead Sciences, Inc.
NEWS
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
Gilead Sciences’ president and chief executive officer, John Milligan, is retiring after 28 years with the company. Gilead is beginning a search for a replacement.
GlaxoSmithKline continues to make headway in the development of two-drug regimens to benefit HIV patients – even those who have high levels of the virus.
Kite, a Gilead company based in Santa Monica, California, signed an agreement with Utrecht, Netherlands-based Gadeta BV. The companies will work on discovering and developing novel cancer immunotherapies based on gamma-delta T-cell receptors (TCRs).
Despite President Trump circling around semi-regularly to bash the pharmaceutical industry and drug prices, biotech stocks seem to be doing pretty well. The Nasdaq Biotechnology ETF, called the IBB, is up about 17 percent so far this year.
Allogene Therapeutics announced the implementation of its Scientific Advisory Board (SAB). The SAB is made up of five leaders in oncology, immunology, drug discovery and development, and will consult on strategic and scientific matters.
Because of the potential for significant side effects of CAR-T therapies, the FDA requires Risk Evaluation and Mitigation Strategies (REMS) programs. The Bezos Family Immunotherapy Clinic at the Seattle Cancer Care Alliance is one of those approved sites.
Gilead may be down, but at least one analyst thinks the company is poised for a turnaround.
Cowen Research’s biotech team published a recent report and concluded that investors would have better luck ignoring—or even doing the complete opposite—of what equity analysts advise.
JOBS
IN THE PRESS